JP2003522198A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522198A5
JP2003522198A5 JP2001558081A JP2001558081A JP2003522198A5 JP 2003522198 A5 JP2003522198 A5 JP 2003522198A5 JP 2001558081 A JP2001558081 A JP 2001558081A JP 2001558081 A JP2001558081 A JP 2001558081A JP 2003522198 A5 JP2003522198 A5 JP 2003522198A5
Authority
JP
Japan
Prior art keywords
group
val
allo
thr
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001558081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522198A (ja
JP5188665B2 (ja
Filing date
Publication date
Priority claimed from GBGB0002952.0A external-priority patent/GB0002952D0/en
Application filed filed Critical
Publication of JP2003522198A publication Critical patent/JP2003522198A/ja
Publication of JP2003522198A5 publication Critical patent/JP2003522198A5/ja
Application granted granted Critical
Publication of JP5188665B2 publication Critical patent/JP5188665B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001558081A 2000-02-09 2001-02-09 カハラリド化合物 Expired - Fee Related JP5188665B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0002952.0 2000-02-09
GBGB0002952.0A GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds
PCT/GB2001/000576 WO2001058934A2 (en) 2000-02-09 2001-02-09 Kahalalide f and related compounds

Publications (3)

Publication Number Publication Date
JP2003522198A JP2003522198A (ja) 2003-07-22
JP2003522198A5 true JP2003522198A5 (enExample) 2008-04-03
JP5188665B2 JP5188665B2 (ja) 2013-04-24

Family

ID=9885232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001558081A Expired - Fee Related JP5188665B2 (ja) 2000-02-09 2001-02-09 カハラリド化合物

Country Status (27)

Country Link
US (2) US7482429B2 (enExample)
EP (3) EP2258715A1 (enExample)
JP (1) JP5188665B2 (enExample)
KR (1) KR100871489B1 (enExample)
CN (2) CN1422278A (enExample)
AT (1) ATE371667T1 (enExample)
AU (1) AU783542B2 (enExample)
BG (1) BG65926B1 (enExample)
BR (1) BR0108213A (enExample)
CA (1) CA2399187C (enExample)
CY (1) CY1106992T1 (enExample)
CZ (1) CZ304258B6 (enExample)
DE (1) DE60130192T2 (enExample)
DK (1) DK1254162T3 (enExample)
ES (1) ES2292558T3 (enExample)
GB (1) GB0002952D0 (enExample)
HU (1) HUP0301817A3 (enExample)
IL (2) IL150981A0 (enExample)
MX (1) MXPA02007760A (enExample)
NO (1) NO331847B1 (enExample)
NZ (1) NZ520488A (enExample)
PL (1) PL207121B1 (enExample)
PT (1) PT1254162E (enExample)
RU (1) RU2280039C2 (enExample)
SK (1) SK11242002A3 (enExample)
UA (1) UA76949C2 (enExample)
WO (1) WO2001058934A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US7473681B2 (en) 2000-10-31 2009-01-06 Pharma Mar, S.A. Kahalalide F
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
CN100396696C (zh) * 2004-04-23 2008-06-25 中国科学院海洋研究所 一种海洋绿藻在提取抗肿瘤活性环肽组分中的应用
CN101861159A (zh) * 2007-10-19 2010-10-13 马尔药品公司 改进的抗肿瘤治疗
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
AU2009221120A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
CN103641891B (zh) * 2013-05-23 2017-03-22 深圳翰宇药业股份有限公司 一种制备Kahalalide F的方法
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程(武汉)有限公司 γ-羟基丁酸的前药及其组合物和用途
KR102510784B1 (ko) 2017-03-30 2023-03-15 엑스더블유파마 리미티드 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程(武汉)有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
WO2021127461A1 (en) 2019-12-20 2021-06-24 Xw Laboratories Limited Methods of synthesizing 4-valyloxybutyric acid
KR102982616B1 (ko) 2020-06-18 2026-06-26 엑스더블유파마 리미티드 수용성 원료의약품의 약학적 과립화제
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
JP2025513295A (ja) * 2022-04-21 2025-04-24 ゼブラ セラピューティクス, インコーポレイテッド ガンマ-ヒドロキシブチラート送達化合物ならびにその作製および使用のためのプロセス

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39496A (en) * 1863-08-11 Improvement in ratchet-drills
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) * 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU658396B2 (en) * 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
EP0567626B1 (en) * 1991-11-19 2001-09-19 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Hgf凍結乾燥製剤
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050406A1 (en) * 1997-05-09 1998-11-12 The General Hospital Corporation Cell proliferation related genes
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
CN1160338C (zh) * 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
JP2004514407A (ja) * 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US7473681B2 (en) 2000-10-31 2009-01-06 Pharma Mar, S.A. Kahalalide F
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Similar Documents

Publication Publication Date Title
AP1398A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
ATE433959T1 (de) Analoge von kokain
JP2002518502A5 (enExample)
JP2004503564A5 (enExample)
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
AU1069001A (en) Quinuclidine acrylamides
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
JP2004502755A5 (enExample)
PL342614A1 (en) Anticarcinogenic drugs
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
EP1431286A3 (en) Prodigiosin derivatives for treating cancer or viral diseases
EP0992509A3 (en) Novel macrolide derivatives
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
HUP0104374A2 (hu) Növekedési hormont felszabadító vegyületek és antagonistáik tumorok kezeléseire való alkalmazásra
JP2004530699A5 (enExample)
JP2005513036A5 (enExample)
DE60212710D1 (de) Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
JP2002522462A5 (enExample)
EP1482933A4 (en) EFFECTIVE SIMPLIFIED DERIVATIVES OF IMMUNOSUPPRESSIVA
JP2003535868A5 (enExample)
WO2001000187A3 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
JP2003523338A5 (enExample)